Stanford Health Policy, Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University School of Medicine and the Freeman Spogli Institute, Stanford, California, USA.
Wellcome Trust Research Laboratory, Christian Medical College, Vellore, Tamil Nadu, India.
J Infect Dis. 2021 Nov 23;224(Supple 5):S612-S624. doi: 10.1093/infdis/jiab150.
Typhoid fever causes substantial global mortality, with almost half occurring in India. New typhoid vaccines are highly effective and recommended by the World Health Organization for high-burden settings. There is a need to determine whether and which typhoid vaccine strategies should be implemented in India.
We assessed typhoid vaccination using a dynamic compartmental model, parameterized by and calibrated to disease and costing data from a recent multisite surveillance study in India. We modeled routine and 1-time campaign strategies that target different ages and settings. The primary outcome was cost-effectiveness, measured by incremental cost-effectiveness ratios (ICERs) benchmarked against India's gross national income per capita (US$2130).
Both routine and campaign vaccination strategies were cost-saving compared to the status quo, due to averted costs of illness. The preferred strategy was a nationwide community-based catchup campaign targeting children aged 1-15 years alongside routine vaccination, with an ICER of $929 per disability-adjusted life-year averted. Over the first 10 years of implementation, vaccination could avert 21-39 million cases and save $1.6-$2.2 billion. These findings were broadly consistent across willingness-to-pay thresholds, epidemiologic settings, and model input distributions.
Despite high initial costs, routine and campaign typhoid vaccination in India could substantially reduce mortality and was highly cost-effective.
伤寒热在全球造成大量死亡,其中近一半发生在印度。新的伤寒疫苗非常有效,世界卫生组织建议在高负担地区使用。需要确定印度是否应该以及应该实施哪种伤寒疫苗接种策略。
我们使用动态房室模型评估伤寒疫苗接种,该模型由最近在印度进行的一项多地点监测研究的疾病和成本数据进行参数化和校准。我们模拟了针对不同年龄和环境的常规和一次性疫苗接种策略。主要结果是成本效益,通过增量成本效益比(ICER)与印度人均国民总收入(2130 美元)进行基准比较来衡量。
由于疾病成本的降低,常规和疫苗接种策略都比现状更具成本效益。首选策略是在全国范围内开展针对 1-15 岁儿童的社区基础追赶性疫苗接种运动,同时常规接种疫苗,其每避免一个残疾调整生命年的成本效益比为 929 美元。在实施的头 10 年,疫苗接种可以避免 2100 万至 3900 万例病例,并节省 16 亿至 22 亿美元。这些发现与支付意愿阈值、流行病学环境和模型输入分布基本一致。
尽管初始成本较高,但在印度进行常规和疫苗接种活动可以大大降低死亡率,并且具有很高的成本效益。